Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without haemodialysis, and in renal transplant patients

B. Lacour, Jean-Baptiste Roullet, P. Beyne, H. Kreis, M. Thevenin, T. Drüeke

Research output: Contribution to journalArticle

Abstract

We investigated serum lipoproteins in uraemic and kidney transplant patients, and compared the results with those from normal persons. In uraemic patients, with or without haemodialysis, and in kidney transplant patients, the ratio of HDL-cholesterol to total cholesterol minus HDL-cholesterol, the ratio of HDL-phospholipids to total phospholipids minus HDL-phospholipids, and the ratio of apolipoprotein A to apolipoprotein B are all decreased, though to different extents, when compared with healthy control subjects. Furthermore, important differences exist in the relative HDL composition between the 3 patient groups and healthy control subjects. Thus, the ratio of apolipoprotein A/HDL-cholesterol and that of HDL-cholesterol/HDL-phospholipids are significantly altered in uraemic haemodialyzed patients, while the ratio of apolipoprotein A/HDL-phospholipids is normal. By contrast, the 3 ratios are normal in uraemic undialyzed patients, and the 2 ratios, apolipoprotein A/HDL-cholesterol and apolipoprotein A/HDL-phospholipids are normal in renal transplant patients. The last ratio, HDL-cholesterol/HDL-phospholipids, is increased in this group of patients. Thus, it appears that HDL-cholesterol, HDL-phospholipids, and total apolipoprotein A represent different aspects of the same lipoprotein. The determination of all three parameters could lead to a different approach in the evaluation of the so-called cardiovascular risk, at least for uraemic patients and renal transplant patients.

Original languageEnglish (US)
Pages (from-to)805-810
Number of pages6
JournalJournal of Clinical Chemistry and Clinical Biochemistry
Volume23
Issue number12
StatePublished - 1985
Externally publishedYes

Fingerprint

Transplants
Apolipoproteins A
Lipoproteins
Chronic Kidney Failure
Renal Dialysis
Phospholipids
HDL Cholesterol
Kidney
Serum
Chemical analysis
Healthy Volunteers
Apolipoprotein A-II
Apolipoproteins B
Cholesterol
Control Groups

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without haemodialysis, and in renal transplant patients. / Lacour, B.; Roullet, Jean-Baptiste; Beyne, P.; Kreis, H.; Thevenin, M.; Drüeke, T.

In: Journal of Clinical Chemistry and Clinical Biochemistry, Vol. 23, No. 12, 1985, p. 805-810.

Research output: Contribution to journalArticle

@article{4c904b841c664bea89c60a62bf7ce2b8,
title = "Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without haemodialysis, and in renal transplant patients",
abstract = "We investigated serum lipoproteins in uraemic and kidney transplant patients, and compared the results with those from normal persons. In uraemic patients, with or without haemodialysis, and in kidney transplant patients, the ratio of HDL-cholesterol to total cholesterol minus HDL-cholesterol, the ratio of HDL-phospholipids to total phospholipids minus HDL-phospholipids, and the ratio of apolipoprotein A to apolipoprotein B are all decreased, though to different extents, when compared with healthy control subjects. Furthermore, important differences exist in the relative HDL composition between the 3 patient groups and healthy control subjects. Thus, the ratio of apolipoprotein A/HDL-cholesterol and that of HDL-cholesterol/HDL-phospholipids are significantly altered in uraemic haemodialyzed patients, while the ratio of apolipoprotein A/HDL-phospholipids is normal. By contrast, the 3 ratios are normal in uraemic undialyzed patients, and the 2 ratios, apolipoprotein A/HDL-cholesterol and apolipoprotein A/HDL-phospholipids are normal in renal transplant patients. The last ratio, HDL-cholesterol/HDL-phospholipids, is increased in this group of patients. Thus, it appears that HDL-cholesterol, HDL-phospholipids, and total apolipoprotein A represent different aspects of the same lipoprotein. The determination of all three parameters could lead to a different approach in the evaluation of the so-called cardiovascular risk, at least for uraemic patients and renal transplant patients.",
author = "B. Lacour and Jean-Baptiste Roullet and P. Beyne and H. Kreis and M. Thevenin and T. Dr{\"u}eke",
year = "1985",
language = "English (US)",
volume = "23",
pages = "805--810",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "12",

}

TY - JOUR

T1 - Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without haemodialysis, and in renal transplant patients

AU - Lacour, B.

AU - Roullet, Jean-Baptiste

AU - Beyne, P.

AU - Kreis, H.

AU - Thevenin, M.

AU - Drüeke, T.

PY - 1985

Y1 - 1985

N2 - We investigated serum lipoproteins in uraemic and kidney transplant patients, and compared the results with those from normal persons. In uraemic patients, with or without haemodialysis, and in kidney transplant patients, the ratio of HDL-cholesterol to total cholesterol minus HDL-cholesterol, the ratio of HDL-phospholipids to total phospholipids minus HDL-phospholipids, and the ratio of apolipoprotein A to apolipoprotein B are all decreased, though to different extents, when compared with healthy control subjects. Furthermore, important differences exist in the relative HDL composition between the 3 patient groups and healthy control subjects. Thus, the ratio of apolipoprotein A/HDL-cholesterol and that of HDL-cholesterol/HDL-phospholipids are significantly altered in uraemic haemodialyzed patients, while the ratio of apolipoprotein A/HDL-phospholipids is normal. By contrast, the 3 ratios are normal in uraemic undialyzed patients, and the 2 ratios, apolipoprotein A/HDL-cholesterol and apolipoprotein A/HDL-phospholipids are normal in renal transplant patients. The last ratio, HDL-cholesterol/HDL-phospholipids, is increased in this group of patients. Thus, it appears that HDL-cholesterol, HDL-phospholipids, and total apolipoprotein A represent different aspects of the same lipoprotein. The determination of all three parameters could lead to a different approach in the evaluation of the so-called cardiovascular risk, at least for uraemic patients and renal transplant patients.

AB - We investigated serum lipoproteins in uraemic and kidney transplant patients, and compared the results with those from normal persons. In uraemic patients, with or without haemodialysis, and in kidney transplant patients, the ratio of HDL-cholesterol to total cholesterol minus HDL-cholesterol, the ratio of HDL-phospholipids to total phospholipids minus HDL-phospholipids, and the ratio of apolipoprotein A to apolipoprotein B are all decreased, though to different extents, when compared with healthy control subjects. Furthermore, important differences exist in the relative HDL composition between the 3 patient groups and healthy control subjects. Thus, the ratio of apolipoprotein A/HDL-cholesterol and that of HDL-cholesterol/HDL-phospholipids are significantly altered in uraemic haemodialyzed patients, while the ratio of apolipoprotein A/HDL-phospholipids is normal. By contrast, the 3 ratios are normal in uraemic undialyzed patients, and the 2 ratios, apolipoprotein A/HDL-cholesterol and apolipoprotein A/HDL-phospholipids are normal in renal transplant patients. The last ratio, HDL-cholesterol/HDL-phospholipids, is increased in this group of patients. Thus, it appears that HDL-cholesterol, HDL-phospholipids, and total apolipoprotein A represent different aspects of the same lipoprotein. The determination of all three parameters could lead to a different approach in the evaluation of the so-called cardiovascular risk, at least for uraemic patients and renal transplant patients.

UR - http://www.scopus.com/inward/record.url?scp=0022365157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022365157&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 805

EP - 810

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 12

ER -